“`html
09/29/2025 – 08:00 PM
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a prominent player in the life science research and clinical diagnostics sectors, announced today the passing of its co-founder and Director Emeritus, Alice N. Schwartz, on September 25, 2025, at the age of 99. Schwartz’s death marks the end of an era for the company she helped build from the ground up.
Founded in 1952 in Berkeley, California, by Alice and her husband David Schwartz, Bio-Rad started with a focus on specialty chemicals for life science research. Alice, a biochemistry graduate from the University of California, Berkeley, played a pivotal role in steering the company’s early technological advancements.
One of Schwartz’s most significant contributions was the development of Bio-Rad’s initial test kit for thyroid function in the 1960s. This innovation, leveraging separation techniques and materials originally designed for life science research, catalyzed Bio-Rad’s expansion into clinical diagnostics. This strategic move proved critical, setting the stage for the company’s sustained growth and dominance in the market. The success of this test kit underscored the potential of translating research-grade technologies into commercially viable diagnostic solutions, a strategy that Bio-Rad would continue to pursue.
Beyond her technical contributions, Schwartz was lauded for her astute business acumen. Her leadership was instrumental in navigating the nascent biotechnology landscape, fostering a culture of scientific curiosity and innovation within Bio-Rad. She remained an active Board member until 2022, consistently championing the company’s commitment to advancing scientific discovery.
Bio-Rad: A Legacy of Innovation
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), headquartered in Hercules, California, maintains a significant global presence in the development, manufacturing, and marketing of products for both life science research and clinical diagnostics. With approximately 7,500 employees worldwide and $2.6 billion in revenue in 2024, the company serves a diverse clientele, including universities, research institutions, hospitals, and biopharmaceutical firms, as well as clinical, food safety, and environmental quality laboratories.
The company’s strategic focus remains on developing innovative, high-quality products that drive scientific advancements and improve healthcare outcomes. Bio-Rad’s enduring commitment to research and development, combined with its extensive distribution network, positions it as a key player in meeting the evolving needs of the global scientific community. Investors are closely watching how Bio-Rad will continue to innovate in areas such as genomics and precision medicine, especially as competition intensifies from both established players and emerging biotech startups.
For more information, visit bio-rad.com.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/10118.html
